Celgene ($CELG) has announced plans to be acquired by Bristol Meyers Squibb ($BMY). A settlement conference is scheduled in the Hatch-Waxman patent case between Celgene and Dr. Reddy’s on January 10, 2019. Now that Bristol Meyers is at the table, will the parties be able to reach a settlement that couldn’t be reached before?
Read MoreIn a slightly new wrinkle in Celgene’s recent Revlimid® saga, Celgene ($CELG) has commenced another suit against Dr. Reddy’s ($RDY). (This is the third patent lawsuit connected to Dr. Reddy’s proposed generic for Revlimid®.) In the most recent suit, Celgene asserts five new patents (the ‘720, ‘977, ‘784, ‘866 and ‘531). The suit was commenced on April 13, 2018 in the federal court in New Jersey, where the other Revlimid® suits are currently pending. What’s this suit all about?
Read More